Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes treated with a lifestyle or metformin (any dose)~* waist circumference \> 88 cm in women and \> 92 cm in men~* BMI 27-40 kg/m2~* triglycerides between 1.0 - 4.0 mmol/L~* LDL \< 4.5 mmol/l~Exclusion Criteria:~* Type 1 diabetes~* Apo E2/2 phenotype~* ALT/AST \> 3x ULN~* GFR \< 60 ml/min, clinically significant TSH outside normal range~* Lipid-lowering drugs other than statins within 6 months~* Current treatment with pioglitazone, insulin, sulphonylureas, gliptins, glinides, SGLT-2 inhibitors or thiazide diuretics (at a dose of \> 25 mg / day)~* Blood pressure \> 160 mmHg systolic and/or \> 105 diastolic~* History of pancreatitis or stomach / other major bleeding, thyroid neoplasia, persistent hypothyroidism or persistent hyperthyroidism~* Any medical condition that puts the patient in the risk of dehydration~* Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.~* Females of childbearing potential who are not using adequate contraceptive methods~* Subjects who have experienced side-effects previously from GLP-1 agonists~* Non-compliance or withdrawal of consent~* Any information or clinical event described in liraglutide SPC that is a contraindication for the use of liraglutide

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): Liraglutide subcutaneous injection once daily with following dose escalation:~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection once daily with following dose escalation:~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).